U.S. markets closed
  • S&P Futures

    4,167.00
    -2.00 (-0.05%)
     
  • Dow Futures

    34,273.00
    -45.00 (-0.13%)
     
  • Nasdaq Futures

    13,386.50
    -0.50 (-0.00%)
     
  • Russell 2000 Futures

    2,218.40
    -4.30 (-0.19%)
     
  • Crude Oil

    65.57
    +0.20 (+0.31%)
     
  • Gold

    1,852.70
    +14.60 (+0.79%)
     
  • Silver

    27.74
    +0.38 (+1.37%)
     
  • EUR/USD

    1.2139
    -0.0007 (-0.06%)
     
  • 10-Yr Bond

    1.6350
    -0.0330 (-1.98%)
     
  • Vix

    18.81
    -4.32 (-18.68%)
     
  • GBP/USD

    1.4090
    -0.0012 (-0.08%)
     
  • USD/JPY

    109.3420
    -0.0050 (-0.00%)
     
  • BTC-USD

    44,893.95
    -3,061.90 (-6.38%)
     
  • CMC Crypto 200

    1,245.45
    -113.11 (-8.33%)
     
  • FTSE 100

    7,043.61
    +80.28 (+1.15%)
     
  • Nikkei 225

    27,956.96
    -127.51 (-0.45%)
     

Should AbbVie Be Worried About Rinvoq?

Keith Speights and Brian Orelli, PhD, The Motley Fool
·3 min read
  • Oops!
    Something went wrong.
    Please try again later.

The U.S. Food and Drug Administration (FDA) has now pushed back two reviews for regulatory filings by AbbVie (NYSE: ABBV) for Rinvoq. This autoimmune disease drug is an important component of the company's growth strategy. In this Motley Fool Live video, recorded on April 7, 2021, Motley Fool contributors Keith Speights and Brian Orelli discuss whether or not AbbVie and its shareholders should be worried about Rinvoq.